The information below is intended only to provide the recommendations and rationale from the Committee to Evaluate Drugs (CED) and the Executive Officer decisions regarding the listing of products on the Formulary or the New Drug Funding Program for cancer care.

Do not rely upon any of the information provided on this site for medical diagnosis or treatment. Please consult your primary health care provider about any personal health concerns. This website does not provide any medical diagnosis, symptom assessment, health counseling or medical opinion for individual users. The information contained on this site is intended for information purposes only and does not constitute medical advice for patients. For more detailed information on prescription drugs, please consult a qualified healthcare professional.

List chronologicallyalphabetically

BRAND NAME	GENERIC NAME	DATE PUBLISHED
Azilect	rasagiline	August 2008
Cipralex	escitalopram	October 2007
Cymbalta – diabetic peripheral neuropathic pain	duloxetine	April 2009
Elaprase	idursulfase	May 2008
Invega	paliperidone	December 2008
Januvia	sitagliptin	December 2010
Leukotriene Receptor Antagonists (Singulair, Accolate)	leukotriene receptor antagonists (montelukast, zafirlukast)	September 2008
Revatio	sildenafil	May 2008
Rituxan	rituximab	January 2008
Tysabri	natalizumab	June 2008
To view PDF format files, you need to have Adobe Acrobat® Reader installed on your computer.    You can download this free software from the Adobe website.